Sign in to view content

The Effect of Intravitreal Afilbercept on Perfusion Status in Patients with Retinal Vascular Disease

Jeffrey S. Heier, MD

Video
Published 2016

Related

Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER Trials
Carl D. Regillo, MD
Annual Meeting Talks
2019
SCORE2 Month 6 to Month 12 Results: 12 Month Outcomes of Treatment Change among Poor Responders at Month 6
Michael S. Ip, MD
Annual Meeting Talks
2018
96-Week Visual and Expanded Anatomical Outcomes of Brolucizumab Versus Aflibercept in Patients With nAMD: Results From HAWK and HARRIER
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2019

Category: Retinal Vascular Disease

See more